Ultragenyx: Q4 Earnings Snapshot

Associated Press Finance
1 min read
0
In this article:

NOVATO, Calif. (AP) — NOVATO, Calif. (AP) — Ultragenyx Pharmaceutical Inc. (RARE) on Thursday reported a loss of $123.2 million in its fourth quarter.

The Novato, California-based company said it had a loss of $1.52 per share.

The results surpassed Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of $1.65 per share.

The biotechnology company posted revenue of $127.4 million in the period, which also topped Street forecasts. Five analysts surveyed by Zacks expected $122 million.

For the year, the company reported a loss of $606.6 million, or $8.25 per share. Revenue was reported as $434.2 million.

Ultragenyx expects full-year revenue in the range of $500 million to $530 million.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RARE at https://www.zacks.com/ap/RARE

Advertisement

Recommended Stories